Recro Pharma (REPH) recently announced that the FDA has granted Recro's appeal of the Complete Response Letter "CRL" for the company's IV Meloxicam product. In the press release, the company cited the FDA's statement that the appeal was granted due to "specific to the request… that the NDA provides sufficient evidence of effectiveness and safety to support approval." So, it appears that IV Meloxicam is essentially approved in the United States. However, the FDA is requiring the company and the agency to come to an agreement on the product's label. So, the company,